<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Metolazone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00524</strong>&#160; (APRD01109)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00524/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00524/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00524.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00524.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00524.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00524.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00524.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00524">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Metolazon</td><td>German</td><td>INN</td></tr><tr><td>Metolazona</td><td>Spanish</td><td>INN</td></tr><tr><td>M&#233;tolazone</td><td>French</td><td>INN</td></tr><tr><td>Metolazonum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Diulo</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Diurem</td><td>Cipla</td></tr><tr><td>Metadure</td><td>Micro Labs</td></tr><tr><td>Metenix</td><td>IFET</td></tr><tr><td>Metolaz</td><td>Navana</td></tr><tr><td>Metolazone</td><td>Sandoz</td></tr><tr><td>Metoral</td><td>Dr. Reddy's</td></tr><tr><td>Metoz</td><td>Centaur</td></tr><tr><td>Metozone</td><td>Ying Yuan</td></tr><tr><td>Mykrox</td><td>Celltech</td></tr><tr><td>Pavedal</td><td>Pharma Investi</td></tr><tr><td>Zaroxolyn</td><td>sanofi-aventis</td></tr><tr><td>Zytanix</td><td>Zydus</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/diuretics">Diuretics</a></li>
<li><a href="/mesh/sodium-chloride-symporter-inhibitors">Sodium Chloride Symporter Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>17560-51-9</td></tr><tr><th>Weight</th><td>Average: 365.835<br>Monoisotopic: 365.06008979</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>16</sub>ClN<sub>3</sub>O<sub>3</sub>S</td></tr><tr><th>InChI Key</th><td>AQCHWTWZEMGIFD-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Naphthyridines</td></tr><tr><th>Subclass</th><td>Quinazolines</td></tr><tr><th>Direct parent</th><td>Quinazolines</td></tr><tr><th>Alternative parents</th><td>Benzenesulfonamides; Toluenes; Chlorobenzenes; Aryl Chlorides; Sulfonamides; Tertiary Carboxylic Acid Amides; Sulfonyls; Tertiary Amines; Polyamines; Carboxylic Acids; Secondary Amines; Organochlorides</td></tr><tr><th>Substituents</th><td>chlorobenzene; toluene; aryl chloride; aryl halide; benzene; sulfonic acid derivative; sulfonamide; tertiary carboxylic acid amide; sulfonyl; tertiary amine; carboxamide group; carboxylic acid derivative; polyamine; carboxylic acid; secondary amine; organochloride; organohalogen; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.</td></tr><tr><th>Pharmacodynamics</th><td>Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.</td></tr><tr><th>Mechanism of action</th><td>The actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. The antihypertensive mechanism of action of metolazone is not fully understood but is presumed to be related to its saluretic and diuretic properties.</td></tr><tr><th>Absorption</th><td>Peak blood levels are obtained within 2 to 4 hours of oral administration. The rate and extent of absorption are formulation dependent. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>50-70% bound to erythrocytes, up to 33% bound to plasma proteins, 2-5% of the drug in circulation is unbound</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Not substantially metabolized. 70-95% is excreted unchanged in urine via glomerular filtration and active tubular secretion. Undergoes enterohepatic recycling. </p></td></tr><tr><th>Route of elimination</th><td>Most of the drug is excreted in the unconverted form in the urine.</td></tr><tr><th>Half life</th><td>Approximately 14 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include difficulty breathing, dizziness, dizziness on standing up, drowsiness, fainting, irritation of the stomach and intestines, and lethargy leading to coma.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Metolazone Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9972</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.5944</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7578</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8113</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5921</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9223</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6466</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8279</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.579</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.923</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.831</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5788</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8234
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7193
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9961
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8955 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9922
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8735
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Gd searle llc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Roxane laboratories inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Ucb inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.ucb.com">UCB Pharma</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Upstate Pharma LLC</li>
<li>Vangard Labs Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>10 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>2.5 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>5 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01078">Deslanoside</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB01396">Digitoxin</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00204">Dofetilide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The thiazide diuretic, metolazone, may increase serum levels of lithium.</td></tr><tr><td><a href="/drugs/DB00469">Tenoxicam</a></td><td>Tenoxicam may antagonize the blood pressure lowering effect of Metolazone. Monitor for changes in the therapeutic effect of Metolazone if Tenoxicam is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The thiazide diuretic, Metolazone, may increase the hypotensive effect of Trandolapril. Metolazone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food to reduce gastric irritation.</li></ul></td></tr></tbody></table>